Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$1.77 USD
+0.01 (0.57%)
Updated Apr 26, 2024 03:46 PM ET
After-Market: $1.78 +0.01 (0.56%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
SONN 1.77 +0.01(0.57%)
Will SONN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SONN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SONN
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
SONN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beat the Market the Zacks Way: Vertiv, Costco, Sonnet BioTherapeutics in Focus
Other News for SONN
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
RNLX, ASLN and SONN among pre-market losers
Sonnet BioTherapeutics announces safety data from Phase 1b/2a trial of SON-080
Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective